Rheumatoid Arthritis and Osteoporosis: A Case Study

Raghavan, PR

doi:10.4172/2167-7921.1000240

Cited by 5 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…have shown that there is an inverse association between vitamin D levels and EPO CKD patients [25]. Vitamin D supplementation and Paricalcitol therapy have been shown to lead to improvement in biomarkers of inflammation [30][31][32][33][34][35][36][37][38][39][40][41][42].…”

Section: Discussionmentioning

confidence: 99%

Metadichol® and Red Cell Distribution Width (RDW) in CKD patients

PR¹

2017

J Stem Cell Res Ther

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Metadichol® and Red Cell Distribution Width (RDW) in CKD patients

PR¹

2017

J Stem Cell Res Ther

View full text Add to dashboard Cite

“…This paper deals with Metadichol ® expression on UCB cells leading to increased CD33 expression similar to what we saw in CD34 expression. The increased expression observed with CD33 could be one possible mechanism that could explain its diverse pharmacological actions of Metadochol ® on multiple diseases [25][26][27][28][29][30][31][32][33][34][35][36][37][38].…”

Section: Carynebacterium Diptheraie Diphteriamentioning

confidence: 99%

Metadichol® and CD33 expression in Umbilical Cord Cells

Raghavan¹

2019

J Stem Cell Res Ther

View full text Add to dashboard Cite

CD33 also known as Siglec-3 is endogenously expressed in stem cells and is a marker for the myeloid lineage of cells. Increased expression of CD33 thus allows it to bind to Sialic Acids (SIAs). These acids are binding sites for pathogens and toxins. By binding to these acids, CD33 can prevent invasion of hosts by these pathogens. Downregulation of CD33, increase the release of the pro-inflammatory cytokine TNF-α by monocytes that increases reactive oxygen species that are involved in diseases like diabetes mellitus, Alzheimer's, cardiovascular diseases asthma, and in various cancers.The up-regulation of CD33 using Metadichol ® was studied using Wharton's Jelly Mesenchymal Stem Cells (MSCs) isolated from human umbilical cord and were grown in p-35 dishes until confluent and treatment was carried out with different concentrations. One dish was untreated and considered as control. The treated and untreated cells were analyzed using Flow Cytometry. The cells treated at 100 pg of Metadichol ® has shown the highest increase (>400 fold) in CD33++ expression (48.77%) compared to untreated control (0.11%).

show abstract

“…Data analysis 1. Compound activity was analyzed using CBIS data analysis suite (ChemInnovation, CA).…”

Section: Micro Plates Were Read Following Signal Generation With a Pementioning

confidence: 99%

“…Metadichol® is a nano formulation of long chain alcohols that is an inverse agonist of Vitamin D receptor [1]. AHR (Aryl hydrocarbon receptor) like VDR a ligand activated transcription factor.…”

Section: Introductionmentioning

confidence: 99%

Metadichol ®. A Novel Inverse Agonist of Aryl Hydrocarbon Receptor (AHR) and NRF2 Inhibitor

Pr¹

2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Metadichol ® a novel nano emulsion of lipid alcohols is an Inverse agonist of Vitamin D Receptor (VDR). In this communication, we show that Metadichol is an inverse agonist of the nuclear receptor AHR (Aryl Hydrocarbon receptor) and also an inhibitor of NRF2 (Nuclear factor (erythroid-derived 2)-like 2) and is a transcription factor that is ubiquitously expressed at low levels in all human organs and regulates a primary cellular defense mechanism, tight regulation to maintain cellular homeostasis. AHR is highly expressed in a broad panel of tumors, AHR is induced by 2,3,7,8-tetrachloride-benzo-p-dioxin (TCDD) Metadichol® as a inverse agonist against AHR could be potentially useful in the treatment of such diseases. Strong in vivo evidence suggests that TCDD can stimulate cross-talk between AHR and Nrf2. The constitutive up regulation of Nrf2 signaling appears to drive the cellular proliferation and resistance to chemotherapy in various cancers. Therefore, pharmacological inhibition of Nrf2 by Metadichol ® holds promise as a therapeutic strategy in chemo resistant forms of cancer.

show abstract

Rheumatoid Arthritis and Osteoporosis: A Case Study

Cited by 5 publications

References 25 publications

Metadichol® and Red Cell Distribution Width (RDW) in CKD patients

Metadichol® and Red Cell Distribution Width (RDW) in CKD patients

Metadichol® and CD33 expression in Umbilical Cord Cells

Metadichol ®. A Novel Inverse Agonist of Aryl Hydrocarbon Receptor (AHR) and NRF2 Inhibitor

Contact Info

Product

Resources

About